GemPharmatech Co., Ltd. (SHA:688046)

GemPharmatech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	344.99	701.37	560.17	421.71	293.52	524.2
Short-Term Investments	76.74	109.33	120.1	-	-	-
Trading Asset Securities	767.7	467.34	637.72	791.24	205.8	-
Cash & Short-Term Investments	1,189	1,278	1,318	1,213	499.31	524.2
Cash Growth	-4.70%	-3.03%	8.66%	142.92%	-4.75%	110.53%
Accounts Receivable	392.91	350.81	269.39	185.45	118.57	90.68
Other Receivables	6.59	6.28	6.09	3.63	39.68	0.16
Receivables	399.5	357.09	275.48	189.08	158.25	90.84
Inventory	58.53	54.2	47.09	49.47	30.08	17.32
Prepaid Expenses	-	-	-	-	3.41	-
Other Current Assets	71.96	20.45	16.96	15.51	15.87	14.89
Total Current Assets	1,719	1,710	1,658	1,467	706.93	647.25
Property, Plant & Equipment	657.86	626.28	624.9	375.15	232.78	163.15
Long-Term Investments	87.9	99.04	175.53	306.94	30.08	-
Other Intangible Assets	48.55	49.05	47.34	48.51	49.53	41.2
Long-Term Deferred Tax Assets	38.49	35.98	31.85	17.05	4.81	5.69
Long-Term Deferred Charges	39.64	40.58	36.68	19.29	24.63	23.83
Other Long-Term Assets	59.1	11.94	3.77	19.77	5.66	2.08
Total Assets	2,651	2,573	2,578	2,254	1,054	883.19
Accounts Payable	65.65	72.18	101.86	50.79	61.73	46.31
Accrued Expenses	28.18	57.42	50.94	46.56	39.04	25.35
Short-Term Debt	139.55	88.04	76.16	12.21	5.15	5.02
Current Portion of Leases	14.4	8.82	9.4	2.61	-	-
Current Income Taxes Payable	6.41	2.84	14.89	4.09	6.44	10.7
Current Unearned Revenue	133.83	138.23	108.42	89.15	75.91	60
Other Current Liabilities	9.96	3.68	4.75	8.66	3.47	2.09
Total Current Liabilities	397.98	371.2	366.41	214.07	191.74	149.47
Long-Term Debt	-	-	-	-	20.03	-
Long-Term Leases	61.89	35.62	36.07	3.05	0.02	-
Long-Term Unearned Revenue	21.23	22.9	41.04	48.99	50.49	70.4
Long-Term Deferred Tax Liabilities	7.94	8.2	9.41	9.9	6.5	6.08
Total Liabilities	489.04	437.92	452.93	276	268.78	225.95
Common Stock	410	410	410	410	360	360
Additional Paid-In Capital	1,262	1,261	1,258	1,254	276.73	273.66
Retained Earnings	517.59	487.61	455.4	313.3	148.63	23.71
Treasury Stock	-35.82	-32.67	-	-	-	-
Comprehensive Income & Other	8.54	8.64	1.09	0.91	0.27	-0.12
Total Common Equity	2,162	2,135	2,125	1,978	785.63	657.24
Shareholders' Equity	2,162	2,135	2,125	1,978	785.63	657.24
Total Liabilities & Equity	2,651	2,573	2,578	2,254	1,054	883.19
Total Debt	215.84	132.48	121.62	17.86	25.2	5.02
Net Cash (Debt)	973.59	1,146	1,196	1,195	474.11	519.18
Net Cash Growth	-12.61%	-4.25%	0.11%	152.07%	-8.68%	122.86%
Net Cash Per Share	2.38	2.82	2.94	3.05	1.33	1.43
Filing Date Shares Outstanding	410	407.41	410	410	410	360
Total Common Shares Outstanding	410	407.41	410	410	360	360
Working Capital	1,321	1,339	1,291	1,253	515.19	497.78
Book Value Per Share	5.27	5.24	5.18	4.82	2.18	1.83
Tangible Book Value	2,113	2,086	2,077	1,929	736.1	616.05
Tangible Book Value Per Share	5.15	5.12	5.07	4.71	2.04	1.71
Buildings	-	324.85	311.67	97.08	97.78	93.13
Machinery	-	263.75	229.67	129.2	93.79	69
Construction In Progress	-	90.85	89.6	171.67	53.02	2.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.